Navigation Links
Accumetrics Appoints John J. Young, MD Chief Medical Officer

SAN DIEGO, Nov. 11 /PRNewswire/ -- Accumetrics, Inc. has announced the appointment of John J. Young, MD as Chief Medical Officer for the company. Dr. Young will serve in a part-time capacity in addition to his current appointment as Professor of Medicine and Director of the Cardiovascular Innovations Program at The Ohio State University in Columbus, Ohio. Dr. Young will serve as the main liaison to practicing clinicians, as well as coordinating ongoing research efforts and educational strategies.

"We are very pleased to welcome John to Accumetrics," said Timothy Still, President and CEO of The Company. "We look forward to leveraging his unique experience as a clinical investigator, as well as clinical expertise to continue to grow our Company."

Prior to joining The Ohio State University Medical Center, Dr. Young was the Co-Director of Cardiovascular Research & Education at the Swedish Heart & Vascular Institute in Seattle, Washington. Prior positions included Associate Director of the Lindner Center for Research & Education, and Director of Interventional Services at the Ohio Heart & Vascular Center, both in Cincinnati, Ohio. Dr. Young received his M.D. from The Ohio State University College of Medicine, where he completed both his Residency and Fellowship training. He also holds a Bachelor of Science degree in chemistry, with honors, from Wright State University, Dayton, OH. Finally, Dr. Young has received the distinction of being one of the "Best Doctors in America," and is a lifetime member of "Who's Who in Medicine & Healthcare."

About Accumetrics (

Accumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.

Accumetrics' VerifyNow(R) System is the first rapid and easy to use platform for measuring an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, Plavix(R), ReoPro(R), and Integrilin(R), the VerifyNow System provides a valuable tool to help physicians make informed treatment decisions.

The Accumetrics logo and VerifyNow are registered trademarks of Accumetrics, Inc., ReoPro is a registered trademark of Centocor, Inc. Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is a registered trademark of Sanofi-Aventis.


Jules Abraham

Lippert/Heilshorn & Associates


SOURCE Accumetrics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Timothy I. Still Appointed CEO at Accumetrics
2. Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board
3. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
4. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
5. NutraCea Appoints New Chief Financial Officer
6. Cardiac Science Appoints Dave Marver as Chief Operating Officer
7. Nutrition 21 Appoints Pam McWilliams, Vice President - General Manager of Direct Response
8. Senesco Appoints Harlan W. Waksal, M.D., to Board of Directors
9. Boston Healthcare Appoints Adam Barak as Vice President Enhancing Its International Pricing and Reimbursement Capability
10. Nikon Instruments Appoints LABSCO its Clinical Distributor in Six States
11. China Pharma Holdings, Inc. Appoints The Ruth Group
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... CITY , Nov. 25, 2015 /PRNewswire/ - Aeterna ... affirms that its business and prospects remain fundamentally ... , Zoptrex™ (zoptarelin doxorubicin) recently received DSMB recommendation ... to completion following review of the final interim ... Phase 2 Primary Endpoint in men with heavily ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... ... genomics company uBiome, were featured on AngelList early in their initial angel funding ... an AngelList syndicate for individuals looking to make early stage investments in the ...
(Date:11/24/2015)... Therapeutics, Inc. (NASDAQ: HALO ) will be presenting at the ... on Wednesday, December 2 at 9:30 a.m. ET/6:30 a.m. PT . ... a corporate overview. th Annual Oppenheimer Healthcare Conference ... a.m. PT . Jim Mazzola , vice president of ... --> th Annual Oppenheimer Healthcare Conference in ...
Breaking Biology Technology:
(Date:11/17/2015)... Paris from 17 th until 19 ... from 17 th until 19 th November 2015. ... invented the first combined scanner in the world which scans ... now two different scanners were required: one for passports and ... the same surface. This innovation is an ideal solution for ...
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/10/2015)... 10, 2015 About signature ... helps to identify and verify the identity of ... as the secure and accurate method of authentication ... particular individual because each individual,s signature is highly ... when dynamic signature of an individual is compared ...
Breaking Biology News(10 mins):